Roche's ($RHHBY) Genentech unit launched a new late-stage trial testing a two-drug combo in melanoma patients, throwing its hat in the ring with GlaxoSmithKline ($GSK), which is testing a rival combo therapy. Report
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!